45,000 Shares in CG Oncology, Inc. (NASDAQ:CGON) Acquired by Alyeska Investment Group L.P.

Alyeska Investment Group L.P. bought a new stake in CG Oncology, Inc. (NASDAQ:CGON - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 45,000 shares of the company's stock, valued at approximately $1,291,000. Alyeska Investment Group L.P. owned about 0.06% of CG Oncology at the end of the most recent reporting period.

Several other large investors have also recently modified their holdings of CGON. Foresite Capital Management VI LLC acquired a new stake in CG Oncology during the fourth quarter worth about $63,712,000. Marshall Wace LLP grew its position in CG Oncology by 18,836.0% in the 4th quarter. Marshall Wace LLP now owns 1,458,072 shares of the company's stock valued at $41,818,000 after acquiring an additional 1,450,372 shares in the last quarter. Wellington Management Group LLP boosted its holdings in CG Oncology by 274.4% in the fourth quarter. Wellington Management Group LLP now owns 1,910,470 shares of the company's stock valued at $54,792,000 after purchasing an additional 1,400,251 shares during the period. Acorn Capital Advisors LLC acquired a new stake in CG Oncology in the fourth quarter valued at $32,451,000. Finally, Decheng Capital LLC lifted its position in CG Oncology by 16.3% in the fourth quarter. Decheng Capital LLC now owns 6,371,669 shares of the company's stock valued at $182,739,000 after acquiring an additional 892,859 shares during the last quarter. Institutional investors own 26.56% of the company's stock.

Insiders Place Their Bets

In other news, Director Leonard E. Post sold 1,000 shares of the business's stock in a transaction dated Monday, April 28th. The stock was sold at an average price of $30.76, for a total transaction of $30,760.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 7.40% of the company's stock.

CG Oncology Stock Up 6.0%

CG Oncology stock traded up $1.43 during mid-day trading on Monday, hitting $25.17. 234,845 shares of the company were exchanged, compared to its average volume of 1,067,847. The company has a market capitalization of $1.92 billion, a PE ratio of -17.72 and a beta of 1.08. The business has a fifty day moving average of $23.57 and a 200 day moving average of $28.47. CG Oncology, Inc. has a 1-year low of $14.80 and a 1-year high of $40.47.

CG Oncology (NASDAQ:CGON - Get Free Report) last announced its earnings results on Tuesday, March 25th. The company reported ($0.48) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.37) by ($0.11). The firm had revenue of $0.46 million for the quarter, compared to analyst estimates of $0.11 million. CG Oncology had a negative return on equity of 18.97% and a negative net margin of 10,642.98%. Research analysts expect that CG Oncology, Inc. will post -1.31 earnings per share for the current year.

Wall Street Analysts Forecast Growth

CGON has been the subject of several recent analyst reports. Cantor Fitzgerald restated an "overweight" rating and issued a $75.00 target price on shares of CG Oncology in a research note on Monday, April 28th. HC Wainwright reissued a "buy" rating and issued a $75.00 price objective on shares of CG Oncology in a research report on Monday, April 28th. JPMorgan Chase & Co. started coverage on CG Oncology in a research note on Friday, May 2nd. They issued an "overweight" rating and a $41.00 price target for the company. Royal Bank of Canada upped their target price on shares of CG Oncology from $66.00 to $68.00 and gave the stock an "outperform" rating in a research report on Tuesday, April 29th. Finally, Scotiabank assumed coverage on shares of CG Oncology in a report on Wednesday, April 16th. They set a "sector perform" rating and a $23.00 target price for the company. One investment analyst has rated the stock with a hold rating, ten have given a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat, the company presently has an average rating of "Buy" and a consensus target price of $57.70.

About CG Oncology

CG Oncology, Inc, an oncolytic immunotherapy company, focuses on developing and commercializing backbone bladder-sparing therapeutics for patients with bladder cancer. The company develops BOND-003 for the treatment of high-risk bacillus calmette guerin (BCG)-unresponsive non-muscle invasive bladder cancer (NMIBC) patients; CORE-001 to treat cretostimogene in combination with pembrolizumab in high-risk BCG-unresponsive NMIBC patients; and CORE-002 for the treatment of cretostimogene in combination with the checkpoint inhibitor nivolumab in muscle invasive bladder cancer patients.